Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cambrex | Contract Pharma

What are you searching for?

Sign in

Search by

Cambrex

Cambrex

Company Headquarters

1 Meadowlands Plaza , East Rutherford, NJ, 07073, US

Driving Directions Phone: View Phone Fax: View Fax
View website

Company Description

Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services.

Request more information from Cambrex

Request more information from Cambrex

Categories from Cambrex

505(b)(2)
Accelerated Stability Studies
Analytical Laboratory Services
Analytical Methods Development
Analytical Validation Studies
Assay Development
Biocatalysis
Blending
cGMP Synthesis
Chromatographic Analysis, LC/GC
Clean Room Services
Clinical Trials, Phase I
Clinical Trials, Phase II
Clinical Trials, Phase III
Clinical Trials, Phase IV
CMC (Chemistry, Manfacturing & Controls)
Container Testing
Contract Development and Manufacturing Organization (CDMO)
Contract Manufacturing
Custom Manufacturing
Custom Synthesis
Dissolution Testing
Dosage Form Development
Drug Development Services
Encapsulation
Environmental Monitoring
Excipients
Extractables / Leachables Testing
Feasibility Studies
Filling, Capsule
Fluid Bed Processing
Forced Degradation Studies
Formulation Development
Formulation Services
Formulation, Controlled Release
Granulation
Hot Melt Extrusion
HPLC
Manufacturing, API
Manufacturing, API, High Potency
Manufacturing, Clinical Trials Supply
Manufacturing, Controlled Substances
Manufacturing, Creams & Ointments
Manufacturing, Custom
Manufacturing, Ethical
Manufacturing, Generics
Manufacturing, High Containment Operations
Manufacturing, Other
Manufacturing, Peptides
Manufacturing, Sustained Release
Methods Development
Methods Validation
Microbiological Testing
Micronization
Mycoplasma Testing
Packaging, Clinical Trial Materials
Particle Size Analysis
Photostability
Preclinical Testing
Preformulation
Process Analytical Technology (PAT)
Process Development/Scale-Up Services
Process R&D
Process Validation Studies
R&D Services
Scale-Up
Size Reduction
Stability Studies
Stability, ICH
Sterility Testing
Supplier, Fine Chemicals
Technology Transfer
Validation, Equipment Cleaning
Validation, Manufacturing
Water Testing: Microbiology

Related Content

Breaking News

Cambrex High Point Site Clears FDA, PMDA, TGA Inspections

High Point facility can now support approved API manufacturing for the U.S., Japan and Australia.

By: Charlie Sternberg

Breaking News

Cambrex Breaks Ground on $30M Milan R&D Facility

New facility will expand analytical development and process R&D capabilities.

By: Charlie Sternberg

Breaking News

Cambrex High Point Site Clears FDA, PMDA, TGA Inspections

High Point facility can now support approved API manufacturing for the U.S., Japan and Australia.

By: Charlie Sternberg

Breaking News

Cambrex Breaks Ground on $30M Milan R&D Facility

New facility will expand analytical development and process R&D capabilities.

By: Charlie Sternberg

Cambrex

Breaking News

Cambrex Advances U.S. and European Expansions

Charles City expansion will add a new API plant with 140,000 liters of capacity and $30M expansion in Milan will add new analytical development and process R&D capabilities.

By: Kristin Brooks

Breaking News

Cambrex Invests $120M to Expand U.S. API Manufacturing Ops

Will support a 40% increase in the Charles City, IA site's large-scale manufacturing capacity, reaching nearly one million liters.

By: Kristin Brooks

Breaking News

Cambrex Expands Peptide Manufacturing Capabilities in Massachusetts

The company expands its API facility in Waltham, MA, to support the development and manufacturing of peptide therapies.

By: Rachel Klemovitch

Collaborations & Alliances

Cambrex Partners with Lilly to Support Biotech Innovation

Will deliver accelerated access to clinical development capabilities for Lilly's biotech collaborators.

Breaking News

Cambrex Expands Stability Storage Business with Durham, NC Facility

New facility will feature advanced storage capabilities and be co-located next to the existing Cambrex analytical facility.

Breaking News

Noramco Acquires Cambrex Drug Product Business Unit

Will provide API customers of Noramco and Purisys, additional service options including drug product formulation development, and manufacturing.

Breaking News

Cambrex Completes $38M Capacity Expansion in North Carolina

Doubles manufacturing capacity with state-of-the-art analytical and chemical development laboratories.

Collaborations & Alliances

Cambrex Expands Snapdragon Chemistry Facility in Massachusetts

Adds an additional 12,000 square feet to Snapdragon's API development and manufacturing facility.

Breaking News

Cambrex Opens New Stability Storage Facility in Belgium

Expands capacity for environmentally controlled stability storage services to the pharmaceutical, medical device and life sciences industries.

Breaking News

Cambrex to Acquire Snapdragon Chemistry

Expands API batch and continuous flow process development and manufacturing.

Breaking News

Cambrex to Invest $16.5M in New R&D Facility and Expansion

R&D facility in Minneapolis expands capacity for small molecule development and manufacturing and expansion in Charles City adds QC lab and office space.

Breaking News

Cambrex Expands Stability Storage in Ireland and Belgium

Q1 Scientific will open a new 20,000-square-foot cGMP facility.

Breaking News

Cambrex Completes First Expansion Phase at Small Molecule API Mfg. Facility in NC

New space adds analytical and chemical development labs totaling 30,000 sq.-ft. and provides future workspace for 85 scientists.